Ketorolac Tromethamine
NDC Package 51662-1295-1

11-digit billing NDC: 51662129501
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Ketorolac Tromethamine is carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1295 and is authorized under FDA application ANDA074802.

Identification & Billing

NDC Package Code
51662-1295-1
Package Description
2 mL in 1 VIAL, SINGLE-DOSE
Product Code
51662-1295
11-Digit Billing Format
51662129501

Clinical Specifications

Proprietary Name
Ketorolac Tromethamine
Dosage Form
-
Usage Information
Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Acute Pain in Adult PatientsKetorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE & ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine injection and narcotics should not be administered in the same syringe (see DOSAGE & ADMINISTRATION – Pharmaceutical Information for Ketorolac Tromethamine Injection).

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
FDA Application #
ANDA074802
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-19-2018
End Marketing Date
04-30-2026
Listing Expiration
04-30-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J1885
Source: ASP
Ketorolac tromethamine inj
HCPCS Dosage 15 MG
Units / Pkg 4

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51662-1295). Click a package code to view its specific billing and regulatory data.

51662-1295-3
25 POUCH in 1 CASE / 1 mL in 1 POUCH (51662-1295-2)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1295-1 identifies a specific commercial package of 2 ml in 1 vial, single-dose of Ketorolac Tromethamine, labeled by Hf Acquisition Co Llc, Dba Healthfirst. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on September 19, 2018. The current certification is valid through April 30, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662129501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1295-1
11-Digit CMS (5-4-2)
51662-1295-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.